Cartesian Therapeutics maintains a 'Buy' rating due to progress in its Descartes-08 cell therapy programs, with pivotal phase 3 trial results for Myasthenia Gravis expected in early 2027 and a potential regulatory filing mid-year. The company is also expanding its therapy into myositis and developing an in vivo CAR-T approach through a partnership with WestGene, with initial data anticipated in the first half of 2027. Strong cash reserves and non-dilutive financing support ongoing clinical and strategic efforts through 2028, positioning the company for continued development and potential growth catalysts.
Cartesian Therapeutics news provides context for readers following health sector stocks. For readers following health sector stocks, here is Pluang's market snapshot as of Oct 30, 2026 01:02 WIB: out of 150 priced US health stocks, 95 rose and 54 fell. Notable movers include Baxter International Inc (BAX) at USD 23.94, down 5.97%, ClearPoint Neuro Inc (CLPT) at USD 11.03, up 4.45% with 100% sell order activity, and AbCellera Biologics Inc (ABCL) at USD 13.07, down 4.18% with 99% sell order activity. Typical hold times range from 11 to 72 days on Pluang.
SAP, a global enterprise software leader, will merge its North Texas operations into a new office in Addison, Texas, relocating about 1,000 employees from Plano and Allen. The new Spectrum Center location will house business operations, software deve...
Ipsos has appointed Mitch Barns as Chairman and CEO for the Americas region, effective November 2, 2026. Barns brings extensive leadership experience from his previous roles as Global CEO of Nielsen and CEO of The Opus Group, positioning him to drive...
UPS plans to handle nearly 70% of holiday packages through automated sorting, using robots and RFID tags to improve efficiency and reduce labor costs. CEO Carol Tomé highlighted that while package volume is intentionally reduced, especially from Amaz...
Polymarket's international prediction market platform experienced an outage after a third-party data provider was hacked, leading to unauthorized withdrawals from user wallets. The company paused trading on the platform, fixed the issue, and plans to...
Mastercard reported robust Q3 results with 14% revenue growth and 21% earnings per share growth, driven by strong operating leverage. Management reaffirmed its guidance and expects continued outperformance. The stock reached a new all-time high, supp...
